The Vanguard Group, Inc. recently announced the acquisition of new stake in TG Therapeutics Inc. (NASDAQ:TGTX). The institutional investor has increased its shareholding in the Healthcare company by 5.24% to 15.15 million shares with purchase of 0.75 million shares. This fresh investment now brings its stake to 10.35% valued currently at $376.07 million. In addition, Darwin Global Management Ltd. raised its holdings by 10.45 million to 10.45 million shares. And Millennium Management LLC has lifted its position by 56.31% or 2.23 million shares – to 6.19 million shares.
With over 2.08 million TG Therapeutics Inc. (TGTX) shares trading Tuesday and a closing price of $28.76 on the day, the dollar volume was approximately $59.78 million. The shares have shown a positive half year performance of 260.85% and its price on 05/23/23 gained nearly 0.63%. Currently, there are 140.31M common shares owned by the public and among those 133.34M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for TGTX have a consensus price objective of $30.50. The analysts have set the share’s price value over the next 12 months at a high of $42.00 and a low of $6.00. The average price target is 3.52% above its recent price level and a downside to the estimated low will see the stock lose -379.33% over that period. But an upside of 31.52% will see the stock hit the forecast high price target while median target price for the stock is $35.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 9 of these insider trades were purchases, accounting for 1,372,660 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 30,000 shares.
The top 3 mutual fund holders in TG Therapeutics Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund. SPDR S&P Biotech ETF owns 4.16 million shares of the company’s stock, all valued at over $103.34 million. The company bought an additional 72820.0 shares recently to bring their total holdings to about 2.84% of the shares outstanding. Vanguard Total Stock Market ETF bought 4997.0 shares to see its total holdings expand to 4.04 million shares valued at over $100.24 million and representing 2.76% of the shares outstanding. Vanguard Small Cap Index Fund bought 10314.0 shares to bring its total holdings to over 3.42 million shares at a value of $85.0 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.34% of the shares outstanding.
However, the script later moved the day high at 29.62, up 0.63%. The company’s stock has a 5-day price change of -5.36% and 70.18% over the past three months. TGTX shares are trading 143.11% year to date (YTD), with the 12-month market performance up to 433.58% higher. It has a 12-month low price of $3.48 and touched a high of $35.67 over the same period. TGTX has an average intraday trading volume of 4.34 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.09%, 28.02%, and 123.18% respectively.
Institutional ownership of TG Therapeutics Inc. (NASDAQ: TGTX) shares accounts for 69.70% of the company’s 140.31M shares outstanding. Mutual fund holders own 29.47%, while other institutional holders and individual stakeholders account for 40.73% and 18.19% respectively.
It has a market capitalization of $4.40B and a beta (3y monthly) value of 2.06. The earnings-per-share (ttm) stands at -$1.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.06% over the week and 7.54% over the month.
Analysts forecast that TG Therapeutics Inc. (TGTX) will achieve an EPS of -$0.27 for the current quarter, -$0.23 for the next quarter and -$0.41 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.42 while analysts give the company a high EPS estimate of -$0.2. Comparatively, EPS for the current quarter was -$0.3 a year ago. Earnings per share for the fiscal year are expected to increase by 44.40%, and 55.80% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate TG Therapeutics Inc. (TGTX) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 0 of the 9 advise that investors “hold,” and 1 rated it as a “Sell.”
Leave a Reply